210 related articles for article (PubMed ID: 24509407)
1. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.
Tarhini AA; Shin D; Lee SJ; Stuckert J; Sander CA; Kirkwood JM
Melanoma Res; 2014 Apr; 24(2):150-7. PubMed ID: 24509407
[TBL] [Abstract][Full Text] [Related]
2. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
Kirkwood JM; Ibrahim J; Lawson DH; Atkins MB; Agarwala SS; Collins K; Mascari R; Morrissey DM; Chapman PB
J Clin Oncol; 2001 Mar; 19(5):1430-6. PubMed ID: 11230488
[TBL] [Abstract][Full Text] [Related]
3. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
4. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
[TBL] [Abstract][Full Text] [Related]
5. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H; Ioannovich J; Dafni U; Stavropoulou-Giokas C; Frangia K; Tsoutsos D; Panagiotou P; Polyzos A; Papadopoulos O; Stratigos A; Markopoulos C; Bafaloukos D; Pectasides D; Fountzilas G; Kirkwood JM
N Engl J Med; 2006 Feb; 354(7):709-18. PubMed ID: 16481638
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunologic basis of interferon therapy in melanoma.
Tarhini AA; Kirkwood JM
Ann N Y Acad Sci; 2009 Dec; 1182():47-57. PubMed ID: 20074274
[TBL] [Abstract][Full Text] [Related]
9. Melanoma adjuvant therapy.
Tarhini AA; Thalanayar PM
Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
[TBL] [Abstract][Full Text] [Related]
13. A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.
Tarhini AA; Lin Y; Yeku O; LaFramboise WA; Ashraf M; Sander C; Lee S; Kirkwood JM
J Transl Med; 2014 Jan; 12():19. PubMed ID: 24457057
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
[TBL] [Abstract][Full Text] [Related]
17. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
Kirkwood JM
Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Eggermont AM; Suciu S; Rutkowski P; Marsden J; Santinami M; Corrie P; Aamdal S; Ascierto PA; Patel PM; Kruit WH; Bastholt L; Borgognoni L; Bernengo MG; Davidson N; Polders L; Praet M; Spatz A
J Clin Oncol; 2013 Oct; 31(30):3831-7. PubMed ID: 24019551
[TBL] [Abstract][Full Text] [Related]
19. Autoimmunity and immunotherapy for cancer.
Koon H; Atkins M
N Engl J Med; 2006 Feb; 354(7):758-60. PubMed ID: 16481646
[No Abstract] [Full Text] [Related]
20. Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines.
Sheng L; Chen X; Wang Q; Lyu S; Li P
Biomed Pharmacother; 2020 May; 125():109966. PubMed ID: 32014686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
